| scholarly article | Q13442814 |
| P50 | author | Milena Vitali | Q54263896 |
| Salvatore Siena | Q28321703 | ||
| Stefano Cascinu | Q38359621 | ||
| P2093 | author name string | M Danova | |
| L Crinò | |||
| E Bajetta | |||
| S Salvagni | |||
| S Del Prete | |||
| I Schiavetto | |||
| P2860 | cites work | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 |
| The Charing Cross Hospital experience with temozolomide in patients with gliomas | Q48836301 | ||
| Survival after brain metastases from breast cancer in the trastuzumab era. | Q48962445 | ||
| Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System | Q57407206 | ||
| Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors | Q58849618 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 | ||
| Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases | Q30881871 | ||
| Identification of prognostic factors in patients with brain metastases: a review of 1292 patients | Q33177750 | ||
| Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life | Q33270398 | ||
| A phase II trial of temozolomide for patients with recurrent or progressive brain metastases | Q33339923 | ||
| Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. | Q33345489 | ||
| Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules | Q33347264 | ||
| Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study | Q33361043 | ||
| Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study | Q33365077 | ||
| Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). | Q33370672 | ||
| Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale). | Q33371852 | ||
| Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors | Q33375710 | ||
| Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer | Q33377758 | ||
| Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents | Q33892805 | ||
| Temozolomide: a novel oral alkylating agent | Q34734267 | ||
| The role of topotecan in the treatment of brain metastases | Q35644836 | ||
| Current management of brain metastases, with a focus on systemic options | Q36246183 | ||
| Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). | Q36611825 | ||
| Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials | Q36857456 | ||
| Multidisciplinary management of brain metastases | Q36900730 | ||
| Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. | Q37054146 | ||
| Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. | Q40060814 | ||
| Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases | Q43573415 | ||
| First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. | Q44003032 | ||
| Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases | Q44119212 | ||
| Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial | Q44942613 | ||
| Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases | Q46825143 | ||
| CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation | Q46979383 | ||
| Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma | Q48090038 | ||
| A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors | Q48231603 | ||
| Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study | Q48244398 | ||
| Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. | Q48411500 | ||
| Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine | Q48479768 | ||
| Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. | Q48514261 | ||
| P433 | issue | 3 | |
| P921 | main subject | lung cancer | Q47912 |
| breast cancer | Q128581 | ||
| neurosurgery | Q188449 | ||
| temozolomide | Q425088 | ||
| brain metastasis | Q1620196 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 655-661 | |
| P577 | publication date | 2009-09-18 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study | |
| P478 | volume | 21 |
| Q30412393 | A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival |
| Q38066590 | Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. |
| Q38222247 | Brain metastasis: new opportunities to tackle therapeutic resistance |
| Q37573461 | Cancer and the metastatic substrate |
| Q38792519 | Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases |
| Q82794554 | Cisplatin and temozolomide combination in the treatment of leptomeningeal carcinomatosis from ethmoid sinus intestinal-type adenocarcinoma |
| Q48806386 | Clinical trial design in brain metastasis: approaches for a unique patient population |
| Q38369616 | Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis |
| Q38036217 | Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide |
| Q33696559 | Current approaches to the treatment of metastatic brain tumours |
| Q36820588 | Development of a preclinical therapeutic model of human brain metastasis with chemoradiotherapy. |
| Q39637384 | Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis |
| Q26824799 | Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer |
| Q85112989 | Implications of modern anticancer therapies for palliative care concepts |
| Q87597521 | Leptomeningeal Metastases |
| Q36939922 | Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. |
| Q26995622 | Melanoma brain metastases: an unmet challenge in the era of active therapy |
| Q54942365 | Meta-analysis of whole-brain radiotherapy plus temozolomide compared with whole-brain radiotherapy for the treatment of brain metastases from non-small-cell lung cancer. |
| Q48121721 | Metastatic melanoma to the brain: surgery and radiation is still the standard of care |
| Q35584731 | Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches. |
| Q38067340 | Optimal management of brain metastases from breast cancer. Issues and considerations |
| Q28072442 | Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases |
| Q48695471 | Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors |
| Q34372972 | Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma |
| Q48471112 | Phase II randomized study of whole-brain radiation therapy with or without concurrent temozolomide for brain metastases from breast cancer |
| Q37641250 | Phase II trial of patupilone in patients with brain metastases from breast cancer |
| Q33401308 | Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. |
| Q33909294 | Profound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner |
| Q33777436 | Progress in the biological understanding and management of breast cancer-associated central nervous system metastases |
| Q48401767 | Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases |
| Q30239901 | Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma |
| Q39652258 | Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions |
| Q37576025 | Temozolomide for treatment of brain metastases: A review of 21 clinical trials |
| Q34762265 | The A/G allele of rs16906252 predicts for MGMT methylation and is selectively silenced in premalignant lesions from smokers and in lung adenocarcinomas |
| Q38532696 | The current management of brain metastasis in melanoma: a focus on riluzole |
| Q90474060 | The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review |
| Q58023833 | Therapie von Hirnmetastasen und Meningeosis neoplastica |
| Q85185650 | Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors |
| Q36057858 | Treatment of Breast Cancer Brain Metastases |
| Q38155202 | Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts |
| Q54509712 | [Progress of treatments in non-small cell lung cancer with brain metastases]. |
Search more.